Implementation of Cloud based Next Generation Sequencing data analysis in a clinical laboratory

Abstract

BackgroundThe introduction of next generation sequencing (NGS) has revolutionized molecular diagnostics, though several challenges remain limiting the widespread adoption of NGS testing into clinical practice. One such difficulty includes the development of a robust bioinformatics pipeline that can handle the volume of data generated by high-throughput sequencing in a cost-effective manner. Analysis of sequencing data typically requires a substantial level of computing power that is often cost-prohibitive to most clinical diagnostics laboratories.FindingsTo address this challenge, our institution has developed a Galaxy-based data analysis pipeline which relies on a web-based, cloud-computing infrastructure to process NGS data and identify genetic variants. It provides additional flexibility, needed to control storage costs, resulting in a pipeline that is cost-effective on a per-sample basis. It does not require the usage of EBS disk to run a sample.ConclusionsWe demonstrate the validation and feasibility of implementing this bioinformatics pipeline in a molecular diagnostics laboratory. Four samples were analyzed in duplicate pairs and showed 100% concordance in mutations identified. This pipeline is currently being used in the clinic and all identified pathogenic variants confirmed using Sanger sequencing further validating the software.

The long tail and rare disease research: the impact of next-generation sequencing for rare Mendelian disorders

“…Investigators at Baylor University and the University of Minnesota have implemented cloudbased bioinformatics workflows, demonstrating increased efficiency and scalability (Onsongo et al, 2014;Reid et al, 2014).…”

Metagenomics in diagnosis and improved targeted treatment of UTI

“…Therefore, the quantitative and qualitative metrics to evaluate a baseline bacterial and fungal profile in normal individuals and UTI patients have to be introduced and validated in multiinstitutional trials to collect more robust data [28]. Assay validation will be a critical step in assessing performance, and it is imperative that standard operating procedures are constructed in order to produce accurate results [29]. Laboratories will need to provide independent verifications of test performance set side by side with other laboratories in order to ensure proficiency.…”

Bioregulatory systems medicine: an innovative approach to integrating the science of molecular networks, inflammation, and systems biology with the patient's autoregulatory capacity?

“…This type of tool could take the form of a diagnostic index based on specific objective routine parameters, like FIB-4 or NIKEI in non-alcoholic fatty liver disease (Demir et al, 2013 ), or prognostically relevant clinical judgment questions (Ganna and Ingelsson, 2015 ), or as a blood-sample based biomarker panel (Mesko et al, 2010 ; Etheridge et al, 2011 ; Hu et al, 2014 ), or as a combination of all mentioned options. With next-generation sequencing costs falling rapidly, some solutions are already being tested for use in the clinical laboratory (Onsongo et al, 2014 ). Some studies indicate that next-generation sequencing solutions may become cost effective (Gallego et al, 2015 ; Li et al, 2015 ).…”